Miracle-dz/UniFAR-FTUs huggingface dataset:
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

Purpose Molecular testing of colorectal cancers (CRCs) to improve patient care and outcomes of targeted and conventional therapies has been the center of many recent studies, including clinical trials. Evidence-based recommendations for the molecular testing of CRC tissues to guide epidermal growth factor receptor (EGFR) -targeted therapies and conventional chemotherapy regimens are warranted in clinical practice. The purpose of this guideline is to develop evidence-based recommendations to help establish standard molecular biomarker testing for CRC through a systematic review of the literature. Methods The American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to develop an evidence-based guideline to help establish standard molecular biomarker testing, guide targeted therapies, and advance personalized care for patients with CRC. A comprehensive literature search that included over 4,000 articles was conducted to gather data to inform this guideline. Results Twenty-one guideline statements (eight recommendations, 10 expert consensus opinions and three no recommendations) were established. Recommendations Evidence supports mutational testing for genes in the EGFR signaling pathway, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize molecular testing for predictive and prognostic molecular biomarkers involve selection of assays, type of specimens to be tested, timing of ordering of tests and turnaround time for testing results. Additional information is available at: www.asco. org/CRC-markers-guideline and www.asco. org/guidelineswiki.
Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children.

BACKGROUND The Republic of Armenia was 1 of the 2 earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program to reduce the burden of rotavirus disease (documented to cause 38% of acute gastroenteritis hospitalizations [AGE] among children aged <5 years). In November 2012, RV1 (Rotarix) was introduced for Armenian infants at ages 6 and 12 weeks. METHODS The established active surveillance system at 2 hospitals in the capital, Yerevan, whereby children aged <5 years hospitalized for AGE have stool sample tested for rotavirus antigen, was used to assess trends in rotavirus hospitalizations. Immunization records on children enrolled after vaccine introduction were obtained from clinics, and vaccine effectiveness (VE) was estimated using children with AGE who test negative for rotavirus as controls for the rotavirus-positive cases. RESULTS Among infants, rotavirus hospitalizations were reduced by 48% within the first year after introduction, and by ≥75% in years 2 and 3 following introduction. Reductions of ≥30% in other young children too old to have been vaccinated suggest additional benefit through indirect protection; overall in year 3, rotavirus hospitalizations were reduced by 69% among children aged <5 years. The overall VE of 2 RV1 doses in protecting against rotavirus hospitalization (any severity) was 62% (95% confidence interval [CI], 36%-77%) among children aged 6-23 months; 68% (95% CI, 24%-86%) among those aged 6-11 months, and 60% (95% CI, 20%-80%) in children aged 12-23 months. Against more severe rotavirus disease, VE was 79% (95% CI, 55%-90%) and similarly high in both age groups. CONCLUSIONS RV1 is effective in young Armenian children and substantially reduced rotavirus hospitalizations shortly after introduction.
Structures Showing Negative Correlations of Signal Intensity with Postnatal Age on T1-weighted Imaging of the Brain of Newborns and Infants

Purpose: Although the neonatal and infantile brain typically shows sequential T1 shortening according to gestational age as a result of myelination, several structures do not follow this rule. We evaluated the relationship between the signal intensity of various structures in the neonatal and infantile brain on T1-weighted imaging (T1WI) and either postnatal or gestational age. Materials and Methods: We examined magnetic resonance images from 120 newborns and infants without any abnormalities in the central nervous system. Written informed consent was obtained from all parents and the institutional review board approved the study. Gestational age at examination ranged from 35 weeks, 3 days to 46 weeks, 6 days, and postnatal age ranged from 7 days to 127 days. Signal intensity on T1WI was evaluated on a scale from Grade 1 (indistinguishable from surrounding structures) to Grade 4 (higher than cortex and close to fat). We evaluated relationships between the T1 signal grades of various structures in the neonatal brain and postnatal or gestational age using Spearman’s correlation analysis. Results: Significant positive correlations were identified between T1 signal grade and gestational age in the pyramidal tract (P < 0.001). Conversely, significant negative correlations were evident between T1 signal grade and postnatal age (P < 0.001), in structures including the stria medullaris thalami, fornix cerebellar vermis, dentate nucleus and anterior pituitary gland. Conclusion: Significant negative correlations exist between signal intensity on T1WI and postnatal age in some structures of the neonatal and infantile brain. Some mechanisms other than myelination might play roles in the course of signal appearance.
Purple corn‐associated rhizobacteria with potential for plant growth promotion

Purple corn (Zea mays var. purple amylaceum) is a native variety of the Peruvian Andes, cultivated at 3000 m since the pre‐Inca times without N fertilization. We aimed to isolate and identify native plant growth‐promoting rhizobacteria (PGPR) for future microbial‐based inoculants.
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

BACKGROUND Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin‐5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid–sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia. METHODS In a 28‐week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma exacerbation rates, lung function, symptoms, and safety were assessed. RESULTS Of 369 patients enrolled, 220 underwent randomization and started receiving benralizumab or placebo. The two benralizumab dosing regimens significantly reduced the median final oral glucocorticoid doses from baseline by 75%, as compared with a reduction of 25% in the oral glucocorticoid doses in the placebo group (P<0.001 for both comparisons). The odds of a reduction in the oral glucocorticoid dose were more than 4 times as high with benralizumab as with placebo. Among the secondary outcomes, benralizumab administered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than the rate with placebo (marginal rate, 0.83 vs. 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual exacerbation rate that was 70% lower than the rate with placebo (marginal rate, 0.54 vs. 1.83, P<0.001). At 28 weeks, there was no significant effect of either benralizumab regimen on the forced expiratory volume in 1 second (FEV1), as compared with placebo. The effects on various measures of asthma symptoms were mixed, with some showing significant changes in favor of benralizumab and others not showing significant changes. Frequencies of adverse events were similar between each benralizumab group and the placebo group. CONCLUSIONS Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV1. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255.)
A SMALL DIRECT SC ACAC CONVERTER WITH CASCADE TOPOLOGY

To realize a small inductor-less AC-AC converter, this paper presents a cascade direct AC-AC converter using switched-capacitor (SC) techniques. The proposed AC-AC converter has cascade topology, where converter blocks with the conversion ratio of 1/2 or 2 are connected in series. Owing to the cascade topology, multiple conversion is performed to realize high conversion ratio. Furthermore, each converter block consists of only two capacitors and four switches, because no flying capacitor is necessary to realize AC-AC conversion. By reducing the number of capacitors, the proposed converter can achieve smaller circuit components and higher input power factor than conventional converters. To clarify the effectiveness of the proposed AC-AC converter, characteristic evaluation was performed by using simulation program with integrated circuit emphasis (SPICE) simulations and theoretical analysis. In the conversion ratio of 1/4, the SPICE simulation result demonstrated that the proposed AC-AC converter can improve 8% power efficiency and 0.4 input power factor from the conventional direct AC-AC converter using flying capacitors.
Efficacy and Safety of REVIVE SE Thrombectomy Device for Acute Ischemic Stroke: River JAPAN (Reperfuse Ischemic Vessels with Endovascular Recanalization Device in Japan)

REVIVE SE (REVIVE) is a closed-ended, self-expanding stent retriever used in the RIVER JAPAN study. We present our early experience with REVIVE for revascularization of acute ischemic stroke (AIS) in patients who have failed or are ineligible for intravenous recombinant tissue plasminogen activator treatment. This prospective, single-arm, non-randomized, multicenter registry study followed up patients undergoing mechanical thrombectomy with REVIVE for 90 days. The primary endpoint was a post-procedure Thrombolysis in Cerebral Infarction (TICI) score ≥2a. Secondary endpoints were clot migration/embolization; recanalization without symptomatic intracranial hemorrhage (ICH) at 24 h; symptomatic ICH; good neurological outcome (modified Rankin Scale score ≤2 National Institute of Health Stroke Scale (NIHSS) score decrease ≥10) at day 90; device- or procedure-related serious adverse events (SAEs) and mortality at day 90. To confirm non-inferiority of REVIVE, results were compared with historical data of the Merci Retriever. About 49 patients were enrolled (median age 73 years; males 46.9%; middle cerebral artery (MCA) occlusion 83.7%; median NIHSS score 17). A post-procedure TICI score ≥2a was observed in 73.5% (36/49, 95% confidence interval [CI] 58.9–85.1) of patients. No post-procedural clot migration/embolization events occurred. Successful recanalization without symptomatic ICH was observed in 62.5% (30/48, 95% CI 47.4–76.0). The good neurological outcome was achieved in 66.7% (32/48) patients. Symptomatic ICH and device- or procedure-related SAEs were reported in 6.3% and 12.2% of patients, respectively. Two deaths were reported. REVIVE demonstrated equivalent efficacy and safety as the Merci Retriever. Results suggest that REVIVE is effective and safe in recanalizing occluded intracranial arteries in AIS.
Arterial Stiffness: A Nexus between Cardiac and Renal Disease

Vascular disease is the leading cause of morbidity and mortality in the Western world, and vascular function is determined by structural and functional properties of the arterial vascular wall. Cardiorenal metabolic syndrome such as obesity, diabetes, hypertension, kidney disease, and aging are conditions that predispose to arterial stiffening, which is a pathological alteration of the vascular wall and ultimately results in target organ damage in heart and kidney. In this review, we provide new insights on the interactions between arterial stiffness, vascular resistance and pulse wave velocity as well as final end-organ damage in heart and kidney. Better understanding of the mechanisms of arterial functional and hemodynamic alteration may help in developing more refined therapeutic strategies aimed to reduce cardiovascular and chronic kidney diseases.
Data-dependent semi-supervised hyperspectral image classification

Hyperspectral imagery provides more powerful information than multispectral remote sensing data. However, when hyperspectral data is used for classification task, the high-dimension features often lead to ill-conditioned problems, such as the Hughes phenomenon. To tackle this problem, various supervised dimensional reduction methods are proposed. However, these methods only exploit the labeled training data and ignore the huge unlabelled data. To utilize the unlabelled data space structure information in dimension reduction, a method is proposed as Data-dependent semi-supervised (DDSS). The proposed method exploits the space structure of labeled data and unlabelled data jointly to reduce the dimensionality of the image cures. Experimental results show that this method significantly outperforms the state-of-the-art dimension reduction methods for classification and denoising.
OVERVIEW OF FIBRE OPTIC SENSING APPLICATIONS TO STRUCTURAL HEALTH MONITORING

Fibre optic sensors have proven to be ideal transdu cers for structural monitoring. Being durable, stable and insensitive to external p erturbations, they are particularly interesting for the long-term health assessment of civil and ge otechnical structures. Many different fibre optic sensor technologies exist and offer a wide ra nge of performances and suitability for different applications. The most widely used sensin g techniques include point sensors (Fibre Bragg Gratings and Fabry-Perot interferometers), lo ng-gauge sensors (SOFO) and distributed sensors (Raman and Brillouin scattering sensors). T hese sensing technologies are now widely used in routine application for health monitoring o f structures such as bridges, buildings, monuments, tunnels, dams, dykes, pipelines, landsli des and many others. This contribution reviews these systems and technologies and presents ome significant application examples, in particular to Bridges, Buildings, Geostructures and Pipelines. 1. FIBER OPTIC SENSORS There exist a great variety of fiber optic sensors (UDD 1991, UDD 1995, INAUDI 1997) for structural monitoring in both the academic and the industrial areas. In this overview we will concentrate on SOFO and DiTeSt sensors. These syste ms for civil health monitoring that have reached an industrial level and have been used in a number of field applications. 1.1. SOFO Displacement Sensors The SOFO system (Figure 1) is a fiber optic displac ement sensor with a resolution in the micrometer range and an excellent long-term stabili y. It was developed at the Swiss Federal Institute of Technology in Lausanne (EPFL) and is n ow commercialized by SMARTEC in Switzerland. The measurement setup uses low-coherence interferom etry to measure the length difference between two optical fibers installed on the structu re to be monitored (Figure 2). The measurement fiber is pre-tensioned and mechanically coupled to the structure at two anchorage points in order to follow its deformation s, while the reference fiber is free and acts as temperature reference. Both fibers are installed insi e the same pipe and the measurement basis can be chosen between 200mm and 10m. The reso lution of the system is of 2 μm independently from the measurement basis and its pr ecision of 0.2% of the measured deformation even over years of operation.
Antibody Epitope of Human α‐Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease

α‐Galactosidase (αGal) is a lysosomal enzyme that hydrolyses the terminal α‐galactosyl moiety from glycosphingolipids. Mutations in the encoding genes for αGal lead to defective or misfolded enzyme, which results in substrate accumulation and subsequent organ dysfunction. The metabolic disease caused by a deficiency of human α‐galactosidase A is known as Fabry disease or Fabry–Anderson disease, and it belongs to a larger group known as lysosomal storage diseases. An effective treatment for Fabry disease has been developed by enzyme replacement therapy (ERT), which involves infusions of purified recombinant enzyme in order to increase enzyme levels and decrease the amounts of accumulated substrate. However, immunoreactivity and IgG antibody formation are major, therapy‐limiting, and eventually life‐threatening complications of ERT. The present study focused on the epitope determination of human α‐galactosidase A against its antibody formed. Here we report the identification of the epitope of human αGal(309–332) recognized by a human monoclonal anti‐αGal antibody, using a combination of proteolytic excision of the immobilized immune complex and surface plasmon resonance biosensing mass spectrometry. The epitope peptide, αGal(309–332), was synthesized by solid‐phase peptide synthesis. Determination of its affinity by surface plasmon resonance analysis revealed a high binding affinity for the antibody (KD=39×10−9 m), which is nearly identical to that of the full‐length enzyme (KD=16×10−9 m). The proteolytic excision affinity mass spectrometry method is shown here to be an efficient tool for epitope identification of an immunogenic lysosomal enzyme. Because the full‐length αGal and the antibody epitope showed similar binding affinities, this provides a basis for reversing immunogenicity upon ERT by: 1) treatment of patients with the epitope peptide to neutralize antibodies, or 2) removal of antibodies by apheresis, and thus significantly improving the response to ERT.
MPDZ controls angiogenesis 1 MPDZ promotes DLL 4-induced Notch signaling during angiogenesis 1

4 Division Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 5 Heidelberg, Germany. 6 European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, 7 68167 Mannheim, Germany. 8 Department of Biochemistry and Molecular Biology, Wise Faculty of Life Science, Tel Aviv 9 University, Tel Aviv, 69978, Israel. 10 Medical Clinic I, Endocrinology and Clinical Chemistry, Heidelberg University Hospital, 11 69120 Heidelberg, Germany. 12
CAB: Cache Aware Bi-tier Task-Stealing in Multi-socket Multi-core Architecture

Modern multi-core computers often adopt a multi-socket multi-core architecture with shared caches in each socket. However, traditional task-stealing schedulers tend to pollute the shared cache and incur more cache misses due to their random stealing. To relieve this problem, this paper proposes a Cache Aware Bi-tier (CAB) task-stealing scheduler, which improves the performance of memory-bound applications by reducing memory footprint and cache misses of tasks running inside the same CPU socket. CAB uses an automatic partitioning method to divide an execution Directed Acyclic Graph (DAG) into the inter-socket tier and the intra-socket tier. Tasks generated in the inter-socket tier are scheduled across sockets, while tasks generated in the intra-socket tier are scheduled within the same socket. Experimental results show that CAB can improve the performance of memory-bound applications up to 68.7% compared with the traditional task-stealing.
Ipsilateral Pleura Radiotherapy Combined Intrapleural with Intravenous Chemotherapy for Patients with NSCLC Presenting Malignant Pleural Effusion

Lung cancer is the leading cause of malignant pleural effusion (MPE) [1-5]. Approximately 15% of lung cancer patients have pleural effusion at the time of initial diagnosis and 50% develop pleural effusion later in their causes [3,5,6]. Patients with pleural effusion have life short expectancy and are difficult to manage clinically [3,4]. A more definitive management strategy is often undertaken with several approaches available to physician or surgeon. These options include repeat thoracentesis, tube thoracostomy with chemical pleurodesis, placement of an indwelling, cuffed, tunned pleural catheter (ICTPC) with or without pleurodesis or medical pleuroscopy or video-assisted theracoscopic surgery (VATS) with pleurodesis [7-16]. The most common therapy for these NSCLC patients with MPE is a tube thoracostomy drainage and intrapleural instillation of a chemical sclerosing agent with or without subsequent systemic chemotherapy [17-19]. Although current mode of therapy can occasionally alleviate the symptoms, the relapse rate is as high as 50% [20].
MULTILIGHTTRACKER: VISION BASED MULTI OBJECT TRACKING ON SEMI-TRANSPARENT SURFACES

This paper describes MultiLightTracker (MLT) a simple and robust system for simultaneous tracking of multiple objects on 2D semi-transparent surfaces. We describe how the system performs object tracking on a surface which can be simultaneously used for back projection, allowing direct and undisturbing singleor multi-user interaction with the projected content. The system is vision based, supporting both 4:3 and 16:9 picture formats, and it requires only a webcam and a recent PC to work. MultiLightTracker currently tracks four different objects simultaneously in real time (~100ms latency) but the aim is to extend this number. In controlled environments such as meeting rooms or living rooms, MultiLightTracker is sufficiently robust for everyday collaborative use. Thus, MultiLightTracker is superior to existing multi-object tracking surfaces with regards to its easy availability, simplicity and comparable low cost.
Morning dosing for dolutegravir‐related insomnia and sleep disorders

AF Capetti, S Di Giambenedetto, A Latini, G Sterrantino, I De Benedetto, MV Cossu and A Gori Ospedale Luigi Sacco-Polo Universitario, Milano, Lombardia, Italy, 2Â° Divisione di Malattie Infettive, Universit~ A Cattolica del Sacro Cuore, Roma, Italy, Unit of Infectious Dermatology, San Gallicano Hospital, Rome, Italy, Infectious Diseases Unit, Careggi University Hospital, Florence, Italy and Azienda Ospedaliera San Gerardo, Monza, Lombardia, Italy